Education
The key aim of GASPH is to facilitate access to education from various providers across the world so that healthcare teams can learn about the appropriate use of antibiotics to support antimicrobial stewardship (AMS).
GASPH acts as a hub for the sharing of e-learning resources and training courses (both open access and fee-based) – you can explore these in the AMS/AMR e-Learning Repository.
There is a separate section of curated resources and publications on COVID-19.
AMS/AMR e-Learning Repository
A curation of searchable peer and non-peer reviewed resources from across the globe
Access repositoryCOVID-19 and AMR
Repository of peer review resources and publications addressing the impact of COVID19 on AMR
Access repositoryThe GASPH repository includes resources from numerous providers and has a filter function to help learners access the topics and formats they require to meet their learning needs.
To facilitate access to resources from key GASPH partners we highlight weblinks that may be helpful:
Center for Infectious Disease Research and Policy (CIDRAP) is based in the USA and works to tackle infectious disease threats through research and the translation of scientific information into real work, practical applications, policies, and solutions. You can find out about their work on AMS here: CIDRAP AMS.
The Commonwealth Pharmacists Association (CPA) is the professional body for national pharmacy associations in Commonwealth countries. In 2018 they launched the Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS), a health partnership programme funded by the UK and the Fleming Fund. This programme has developed a suite of resources to tackle antimicrobial resistance (AMR) globally by supporting teams with implementing antimicrobial stewardship to tackle AMR. These resources can be accessed here: CPA AMR.
ESCMID Study Group for Antimicrobial Stewardship (ESGAP) The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) aims to improve the diagnosis, treatment and prevention of infection-related diseases by promoting and supporting research, education, training, and good medical practice. The work of their AMS group is available here: ESCMID-ESGAP AMS.
The Fleming Fund supports low- and middle-income countries to generate, share and use data to improve antimicrobial use and encourage investment in AMR through a variety of projects. Their education resources can be accessed here: Fleming Fund Resources.
The International Society of Antimicrobial Chemotherapy (ISAC) is a federation of 95 affiliated Member Societies which aims to increase the knowledge of antimicrobial chemotherapy and combat antibiotic resistance around the world. The ISAC Academy is an e-learning resource which hosts both ISAC and stakeholder educational material here: ISAC Academy World.
One Health Trust (OHT) uses research and stakeholder engagement to improve the health and well-being of our planet and its inhabitants. OHT builds on the work of the Center for Disease Dynamics, Economics & Policy (CDDEP), which for more than a decade conducted vitally important research on major global health challenges, including COVID-19, antimicrobial resistance, hospital infections, tuberculosis, malaria, pandemic preparedness and response, vaccination, medical oxygen shortages, and noncommunicable diseases. Find out about OHT’s work on AMR here: OHT AMR focus.
Making superbugs visible filing AMR: Filmmaker Michael Wech illustrates the problem with a series of stories about real people in his documentary “The Silent Pandemic”.
The Global Health Network (TGHN) hosts an AMR Community of Practice, and their Knowledge Hub supports stronger coordination, knowledge sharing, and faster progress in AMR research across the Globe. Their resources can be accessed here: TGHN/AMR.
The World Health Organisation (WHO) developed the Global Action Plan for AMR and supports action across all healthcare economies via a variety of education resources and toolkits: WHO AMS courses.
We are a global educator, joining the dots between scientific researchers, medical communities and the wider public to stop the growing threat of drug-resistant infections